Literature DB >> 34775495

microRNA-155-5p initiates childhood acute lymphoblastic leukemia by regulating the IRF4/CDK6/CBL axis.

Xiaojun Sun1, Guotao Guan1, Yunpeng Dai1, Ping Zhao1, Liying Liu1, Qi Wang1, Xiuli Li2.   

Abstract

Acute lymphoblastic leukemia (ALL) is a common malignancy in children. In this study, we aimed to explore putative mechanisms of microRNA-155-5p (miR-155-5p) involvement in childhood ALL (cALL) via interactions with casitas B-lineage lymphoma (CBL), interferon regulatory factor 4 (IRF4), and cyclin-dependent kinase 6 (CDK6). Bioinformatic analysis was performed initially to identify differentially expressed genes in cALL. The expression levels of miR-155-5p, CBL, IRF4, and CDK6 in peripheral blood lymphocytes from clinical ALL samples were determined using RT-qPCR and Western blot assays. A dual-luciferase reporter gene assay was used to ascertain a possible targeting relationship between miR-155-5p and CBL, CCK-8 assay and flow cytometry were used to measure cell activity and apoptosis of ALL cells. Co-IP was performed to investigate the interaction between CBL and IRF4 and the ubiquitination level of IRF4. Furthermore, in vivo validation was performed inducing xenograft tumor models with ALL cells in nude mice. As indicated by bioinformatic analysis, miR-155-5p and CDK6 were upregulated and CBL was downregulated in ALL. miR-155-5p was found to target CBL to inhibit CBL expression. miR-155-5p promoted the proliferation of ALL cells and inhibited their apoptosis by inhibiting the expression of CBL, which otherwise degraded IRF4 protein through ubiquitination, leading to inhibited CDK6 expression. Collectively, the results show that miR-155-5p can promote the development of cALL via the regulation on CBL-mediated IRF4/CDK6 axis.
© 2021. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34775495     DOI: 10.1038/s41374-021-00638-x

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  4 in total

Review 1.  Treatment of relapsed/refractory acute lymphoblastic leukemia.

Authors:  Shilpa Paul; Caitlin R Rausch; Patrice E Nasnas; Hagop Kantarjian; Elias J Jabbour
Journal:  Clin Adv Hematol Oncol       Date:  2019-03

2.  MiR-155 inhibits proliferation, invasion and migration of melanoma via targeting CBL.

Authors:  H Li; J-B Song; H-X Chen; Q-Q Wang; L-X Meng; Y Li
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-11       Impact factor: 3.507

3.  Overexpressed miR-155 is associated with initial presentation and poor outcome in Chinese pediatric acute myeloid leukemia.

Authors:  L-H Xu; Y Guo; J-N Cen; W-Y Yan; H-L He; Y-N Niu; Y-X Lin; C-S Chen; S-Y Hu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2015-12       Impact factor: 3.507

4.  MicroRNA-155 regulates the proliferation, cell cycle, apoptosis and migration of colon cancer cells and targets CBL.

Authors:  Hua Yu; Weiling Xu; Fangchao Gong; Baorong Chi; Junyi Chen; Ling Zhou
Journal:  Exp Ther Med       Date:  2017-08-31       Impact factor: 2.447

  4 in total
  1 in total

Review 1.  MicroRNAs and the Diagnosis of Childhood Acute Lymphoblastic Leukemia: Systematic Review, Meta-Analysis and Re-Analysis with Novel Small RNA-Seq Tools.

Authors:  Ioannis Kyriakidis; Konstantinos Kyriakidis; Aspasia Tsezou
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.